Services-Testing Laboratories
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Sector
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Net Margin | -2.7% | -12% | -4.4% | 0.95% | 2% | 0.94% | -1.7% | -28% | -15% | -14% |
ROA | -1.2% | 0.76% | 0.68% | 2% | 1.8% | -1.4% | -0.81% | -9.1% | -5.8% | -5.6% |
ROE | -1.3% | -19% | -6.6% | 0.82% | 1.6% | 0.6% | -0.75% | -14% | -9.3% | -9.1% |
The average Net Margin over the past 5 years is -6.84%.
The trend of Net Margin over the past 5 years is -4.93%.
The average ROA over the past 5 years is -2.21%.
The trend of ROA over the past 5 years is -2.03%.
The average ROE over the past 5 years is -3.59%.
The trend of ROE over the past 5 years is -2.87%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Debt FCF | 17.08 | 8.45 | 26.89 | 4.20 | 31.57 | -6.22 | -5.87 | -5.53 | -17.53 | -13.61 |
Debt Equity | 0.34 | 0.72 | 0.68 | 0.40 | 0.21 | 0.25 | 0.48 | 0.54 | 0.57 | 0.58 |
MIN | ||||||||||
Graham Stability | - | - | - | - | - | - | -170% | -11K% | - | -11K% |
The Debt/FCF trailing twelve month is -13.61.
The trend of Debt/FCF over the past 5 years is -6.27.
Graham’s Stability measure stands at -112.96.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
---|---|---|---|---|---|
Revenue | 13% | 16% | 10% | 16% | -6.7% |
Net Income | - | - | - | - | -250% |
Stockholders Equity | 28% | 24% | 11% | -5.7% | -15% |
FCF | - | - | - | - | 24% |
The Revenue CAGR over the past 5 years is +16.41%.
The trend of Revenue growth rate over the past 5 years is -6.74%.
The Earnings CAGR over the past 5 years is -.
The trend of Earnings growth rate over the past 5 years is -251.15%.
The Equity CAGR over the past 5 years is +24.06%.
The trend of Equity growth rate over the past 5 years is -15.25%.
The FCF CAGR over the past 5 years is -.
The trend of FCF growth rate over the past 5 years is +24.22%.